Orally administered material temporarily coats the intestine, reduces blood sugar spikes in preclinical study
Over the last decade, bariatric surgeons have made strides in performing weight loss surgery that not only reverses obesity but can also reverse type 2 diabetes in patients with both conditions. Despite dramatic improvements in quality of life and diabetes remission, the number of patients who pursue surgery remains relatively low, according to Ali Tavakkoli, MD, co-director of the Center for Weight Management and Metabolic Surgery at BWH. This prompted a collaboration between Tavakkoli and Brigham and Women’s Hospital researchers to find a less invasive but equally effective treatment for reversing type 2 diabetes, one that can offer the same benefits as surgery but that may have wider appeal and application. In a paper published this week in Nature Materials, the team reports on results of a preclinical study in which an oral agent was administered in rats to deliver a substance that could temporarily coat the intestine to prevent nutrient contact with the lining in the proximal bowel and avoid post-meal spikes in blood sugar.
“We envision a pill that a patient can take before a meal that transiently coats the gut to replicate the effects of surgery,” said co-senior author Jeff Karp, PhD, a bioengineer and principal investigator at BWH. “Over the last several years, we’ve been working with our surgical colleagues on this idea and have developed a material that meets an important clinical need.”
The team members searched for a starting material that would have just the right properties to adhere to the small intestine and then dissolve within a matter of hours. They selected a substance known as sucralfate, an FDA-approved drug that is used in the treatment of gastrointestinal ulcers. The team further engineered the substance into a novel material that can coat the lining of the intestine without requiring activation by gastric acid. The engineered compound, referred to as LuCI (Luminal Coating of the Intestine), can be made into a dry powdered form that can be encapsulated as a pill.
“What we’ve developed here is essentially, ‘surgery in a pill,'” said co-lead author Yuhan Lee, PhD, a materials scientist in the BWH Division of Engineering in Medicine. “We’ve used a bioengineering approach to formulate a pill that has good adhesion properties and can attach nicely to the gut in a preclinical model. And after a couple of hours, its effects dissipate.”
The team found that once in the intestine of rats, LuCI can coat the gut, forming a thin barrier that alters nutrient contact and lowers blood glucose response after a meal. After a meal, blood sugar levels rise and can stay elevated over time. However, one hour after LuCI was administered to the rats, the response to glucose was lowered by 47 percent. The team found that this response was temporary, and after three hours, the effect essentially disappeared.
The team is now testing the effect of short- and long-term use of LuCI in diabetic and obese rodent models. They also plan to advance some of their pilot studies showing that LuCI can be used to deliver drugs, including proteins directly to the gastrointestinal tract.
“Gastric bypass is one of the best studied surgeries in the world, and we know that it can lead to many benefits including positive effects for blood pressure, sleep apnea and certain forms of cancer, and a remarkably fast and weight-independent improvement in diabetes,” said Tavakkoli, co-senior author of the study. “Having a transient coating that could mimic the effects of surgery would be a tremendous asset for patients and their care providers.”
The Latest on: Type 2 diabetes
via Google News
The Latest on: Type 2 diabetes
- Type 2 diabetes: One of the best diets to help with insulin resistance and obesityon November 23, 2020 at 7:50 am
TYPE 2 diabetes is a tricky condition which will get worse over time if a person is not vigilant with their diet and food they put in their bodies. The good news is that by following an ...
- Should I switch to a plant-based diet if I have type 2 diabetes?on November 23, 2020 at 2:30 am
Susan Neuman can still recount a saying her grandmother brought “from the old country — “What a man eats, a man is.” ...
- Five diet and exercise swaps to lower your risk of type 2 diabetes at homeon November 21, 2020 at 12:32 pm
DIABETES is a common condition that affects almost five million people in the UK. But you could lower your risk of type 2 diabetes and high blood sugar symptoms with just a few simple lifestyle swaps.
- Study suggests link between type 2 diabetes and cardiovascular riskon November 20, 2020 at 9:49 am
Even people who control their diabetes at an optimal level may have a higher level of cardiovascular disease risk, new research suggests.
- The Prospects of Semaglutide for Treatment of Type 2 Diabetes Patientson November 20, 2020 at 3:55 am
Medical talks to Dr. Jan Westerink about recent studies into Novo Nordisk’s semaglutide and its potential benefits for Type 2 Diabetes patients, that he and Novo Nordisk collaborated on.
- Drs. Oz & Roizen: Beating back Type 2 diabetes complications one sip at a timeon November 19, 2020 at 5:08 pm
In 2012, a Brooklyn bagel maker offered a special beverage called Larry King Sunrise Coffee to honor the broadcast journalist, who served as the company’s spokesman. King, who has Type ...
- Global Type-2 Diabetes Market Analysis, Share, Growth, Trends, Top Key Players and Forecast 2025on November 19, 2020 at 1:14 pm
Diabetes Market Analysis, 2020a??, the Global Type-2 Diabetes market is anticipated to grow at a CAGR of around 8% during 2020-25. Based on gender segment, women acquired the substantial market share ...
- Altered gut microbiota increases production of molecules that may contribute to type 2 diabeteson November 19, 2020 at 6:08 am
It is the bacterial changes in the gut that increase the levels of imidazole propionate, the molecule that makes the body's cells resistant to insulin in type 2 diabetes. This result emerges from a ...
- Lilly's Jardiance reduced risk of cardiovascular events in adults with type 2 diabeteson November 18, 2020 at 10:46 am
(NYSE:LLY) and Boehringer Ingelheim reports results from EMPA-REG OUTCOME trial assessing Jardiance and placebo, both added to standard of care in adults with type 2 diabetes and established ...
via Bing News